Tris Pharma receives ex-US approvals for ADHD treatments

Tris Pharma has received additional ex-US approvals for its ADHD treatments, Quillivant XR and QuilliChew ER.

Nov 21, 2024 - 06:00

Tris Pharma receives ex-US approvals for ADHD treatments

Tris Pharma has received additional ex-US approvals for its ADHD treatments, Quillivant XR and QuilliChew ER.

Read the original article

Tags:

Previous Article

KM Biologics’ mpox vaccine approved for emergency use by WHO

Veeva Commercial Summit: Increased investment in medical affairs by pharma compa...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

CD70 CAR-T by UTC Therapeutics for B-Cell Non-Hodgkin L...

Aug 10, 2023

Opinion: Your health insurance may not be as good your state requires — and it’s perfectly legal

Opinion: Your health insurance may not be as good your ...

Jun 10, 2023

STAT+: Courts will decide the future of Medicare’s power to negotiate drug prices within months

STAT+: Courts will decide the future of Medicare’s powe...

Jan 12, 2024